Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure
Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure
复制标题
DOI：
10.1136/gut.45.4.559
复制
发表时间：
1999-10-01
期刊：
影响因子：
24.5
通讯作者：
Mortensen, PB
中科院分区：
文献类型：
--
作者：
Jeppesen, PB;Hartmann, B;Mortensen, PB
背景--GLP-2是啮齿类动物肠道上皮细胞的一种生长因子，可能影响肠道运输。目的-研究7例短肠功能衰竭患者和7名对照组的GLP-2对营养摄入的反应。方法：患者和对照组在禁食一晚后两次进餐。A餐为液体(300ml1.88MJ)，B餐为普通早餐(755g，3.92MJ)。采集血浆样本180分钟，用氨基末端特异性放射免疫分析法检测GLP-2免疫反应性。这些反应的幅度和持续时间取决于餐量：A餐和B餐的最大中位数(25-75%)分别升高24(3-28)和48(33-56)pmol/L，A餐后180min血浆GLP-2恢复到基础水平，但B餐后仍维持在峰值的50%。B餐后GLP-2的最大中位数升高为5(2-8)pmol/L。A餐和B餐对GLP-2的反应在患者和对照组之间有显著差异。结论：GLP-2是一种组织特异性的肠道生长因子，证明短肠患者餐刺激的GLP-2反应受损，可能成为一种新的治疗策略，增强回肠切除短肠并肠衰竭患者的空肠适应性。
Background-Glucagon-like peptide 2 (GLP-2) is a growth factor for the intestinal epithelium in rodents and may affect intestinal transit.Aims-To study the GLP-2, response to nutrient ingestion in seven short bowel patients with intestinal failure and seven controls.Methods-The patients and controls were admitted twice for two test meals after a night of fasting. Meal A was liquid (300 ml 1.88 MJ); meal B was a regular breakfast (755 g, 3.92 MJ). Plasma samples were collected for 180 minutes; GLP-2 immunoreactivity was measured with an NH, terminal specific radioimmunoassay.Results-Both meals elicited significant increases in plasma GLP-2 in controls. The magnitude and duration of the responses were dependent on the meal size: the maximum median (25-75%) increases after meal A and B were 24 (3-28) and 48 (33-56) pmol/l. Plasma GLP-2 returned to basal concentrations 180 minutes after meal A, but remained at 50% of peak values after meal B. In the patients neither meal significantly changed the GLP-2 concentration; the maximum median elevation after meal B was 5 (2-8) pmol/l. There were significant differences between patients and controls with respect to the GLP-2 responses to meals A and B.Conclusion-Identification of GLP-2 as a tissue specific intestinal growth factor and demonstration of an impaired meal stimulated GLP-2 response in short bowel patients raises the possibility that GLP-2 administration may constitute a new therapeutic strategy, enhancing jejunal adaptation in ileum resected short bowel patients with intestinal failure.